^
Association details:
| Biomarker: | EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-075 - Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
Published date:
07/12/2022
Excerpt:
A 59-year old female...Cytologic material obtained by EBUS-FNA of stations 4R, 4L, and 11R, revealed metastatic pulmonary adenocarcinoma….Oncomine™ Comprehensive Assay v.3 in February 2022 revealed the following mutations: EGFR p.L747_A750delinsP (i.e., the known ex19del, now more specified), ATM p.S1455fs*36, most likely a loss-of-function mutation, and the rare pathogenic MYC variant c.184G>A, p.E62K....The patient initiated Erlotinib 150 mg daily in March 2014, obtained a partial response by June 2014, and gradually reached complete remission (CR) in May 2015. The CR has persisted ever since (latest CT scan in February 2022).
